SS Innovations Reports Record Q2 Revenue, Expanding Global Reach of Surgical Robotics

SS Innovations International (NASDAQ: SSII) has announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year. The company's SSi Mantra surgical robotic system saw installations rise 30.4% to 30 during the quarter, contributing to a cumulative installed base of 224 systems across 12 countries as of June 30.

The financial results underscore a period of robust growth for the company. Gross profit climbed 20% to $7.1 million, with a gross margin of 50.9%. While the company reported a net loss of $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million a year earlier, the first-half performance was particularly strong. Revenue for the first half of 2026 increased 65.6% to $25 million, and SSi Mantra installations surged 47.4% to 56.

Beyond the numbers, SS Innovations is making strides in demonstrating the capabilities of its technology. As of June 30, the company had completed 12,272 cumulative procedures using the SSi Mantra, including 175 telesurgeries. Notably, the company recently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, showcasing the potential for remote surgical expertise to reach underserved regions.

The company is also progressing toward regulatory milestones. SS Innovations expects the U.S. Food and Drug Administration (FDA) to complete its review of the SSi Mantra's 510(k) premarket notification by the end of the first quarter of 2027. Additionally, the company believes it can obtain European Union CE marking certification by the end of 2026. These approvals would open doors to major markets, potentially expanding access to affordable robotic surgery globally.

The implications of this growth are significant for the healthcare industry. SS Innovations aims to make robotic surgery more affordable and accessible, addressing a critical gap in global healthcare. With an American company headquartered in India, the company is strategically positioned to serve both developed and emerging markets. The company's balance sheet remains solid with $13.6 million in cash and cash equivalents and no long-term debt, providing a foundation for continued expansion.

As SS Innovations continues to scale, its progress could reshape the competitive landscape of surgical robotics, challenging established players and offering new opportunities for hospitals and patients worldwide. The company's focus on telesurgery also hints at a future where geographic barriers to specialized surgical care are diminished, potentially improving outcomes for patients in remote areas.

For more information, visit the company's newsroom at https://ibn.fm/SSII.